Human mena (hMENA), a member of the actin cytoskeleton regulators Ena/VASP, is overexpressed in high-risk preneoplastic lesions and in primary breast tumors and has been identified as playing a role in invasiveness and poor prognosis in breast cancers that express HER2. Here we identify a unique isoform, hMENAΔv6, derived from the hMENA alternative splicing program. In an isogenic model of human breast cancer progression, we show that hMENA 11a is expressed in premalignant cells, whereas hMENAΔv6 expression is restricted to invasive cancer cells. "Reversion" of the malignant phenotype leads to concurrent down-regulation of all hMENA isoforms. In breast cancer cell lines, isoform-specific hMENA overexpression or knockdown revealed that in the absence of hMENA 11a , overexpression of hMENAΔv6 increased cell invasion, whereas overexpression of hMENA 11a reduced the migratory and invasive ability of these cells. hMENA 11a splicing was shown to be dependent on the epithelial regulator of splicing 1 (ESRP1), and forced expression of ESRP1 in invasive mesenchymal breast cancer cells caused a phenotypic switch reminiscent of a mesenchymal-to-epithelial transition (MET) characterized by changes in the cytoskeletal architecture, reexpression of hMENA 11a, and a reduction in cell invasion. hMENA-positive primary breast tumors, which are hMENA 11a -negative, are more frequently E-cadherin low in comparison with tumors expressing hMENA 11a . These data suggest that polarized and growth-arrested cellular architecture correlates with absence of alternative hMENA isoform expression, and that the hMENA splicing program is relevant to malignant progression in invasive disease.ENA along with VASP and EVL comprise the Ena/VASP family of actin regulatory proteins, which modulate cell adhesion and migration by antagonizing actin capping proteins (1, 2), bundling actin filaments, and nucleating and extending filopodia (1-7). The MENA gene encodes the 570-aa hMENA protein and different alternative splicing-derived isoforms, often expressed in a tissue-specific manner, have been reported in human (8, 9) and mouse (1, 10, 11). The neuronal variant is characterized by an extended exon 6 (1, 8), the spleen-specific variant lacks the proline-rich region (10), and an invasion-specific splice variant (MENA INV ), with an additional exon just after the EVH1 domain, has been shown to regulate chemotaxis in mouse and rat mammary tumor cells (12). Previously, we characterized hMENA 11a , an epithelial-associated hMENA splice variant with an additional exon (exon 11a) (9). hMENA 11a , expressed in human pancreatic (13) and breast cancer cells (9), is phosphorylated downstream of HER2 and EGFR following EGF and NRG1 treatment and in turn influences the mitogenic signals of these receptors in luminal breast cancer cell lines (9,14).hMENA isoforms, undetectable in normal breast tissue, are progressively expressed in premalignant breast lesions, suggesting that their presence could be used as an early stage marker of breast neoplasia in women at a hig...